2-甲氧基聚硅氧烷 | 102575-24-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 中文名称: 2-甲氧基聚硅氧烷
• 英文名称: 2-methoxy-idazoxan
• 英文别名: RX 821002；[3H]-2-(2,3-dihydro-2-methoxy-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole；2-(2,3-dihydro-2-methoxy-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole；2-(2-methoxy-2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole；2-(2-methoxy-3H-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole；(+/-)-2-(2-methoxy-1,4-benzodioxan-2-yl)-2-imidazoline；2-Methoxyidazoxan；2-(3-methoxy-2H-1,4-benzodioxin-3-yl)-4,5-dihydro-1H-imidazole
• CAS: 102575-24-6
• 化学式: C₁₂H₁₄N₂O₃
• 分子量: 234.255
• InChiKey: HQGWKNGAKBPTBX-UHFFFAOYSA-N

物化性质

• 沸点：
  407.9±45.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  52.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-甲氧基聚硅氧烷 生成 (+)-(S)-2-(2-methoxy-1,4-benzodioxan-2-yl)-2-imidazoline
  参考文献：
  名称：

  .alpha.-Adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional .alpha.2-adrenoreceptor antagonists

  摘要：

  The resolution of three 2-substituted derivatives of idazoxan is described. The enantiomers show large separations in activity in a variety of in vitro and in vivo tests, and the active isomers are all potent and selective antagonists at the alpha 2-adrenoreceptor. The significance of these results in relation to those published on the enantiomers of idazoxan and to those on optically active alpha 2-adrenoreceptor agonists is discussed.

  DOI：

  10.1021/jm00160a033
• 作为产物：
  描述：

  2,3-二氢苯并[1,4]二恶烷-2-甲腈 在 盐酸 、 N-溴代丁二酰亚胺(NBS) 、 过氧化氢苯甲酰 作用下， 以 四氯化碳 、 乙醚 为溶剂， 反应 45.0h， 生成 2-甲氧基聚硅氧烷
  参考文献：
  名称：

  .alpha.-Adrenoreceptor reagents. 3. Synthesis of some 2-substituted 1,4-benzodioxans as selective presynaptic .alpha.2-adrenoreceptor antagonists

  摘要：

  The synthesis and pharmacological activity of a series of 2-substituted derivatives of the selective alpha 2-adrenoreceptor antagonist idazoxan (RX 781094) is described. Substitution in this position by alkyl, alkenyl, cycloalkenyl, and alkoxy groups in many cases gives compounds whose potencies and selectivities are significantly greater than those of the parent compound.

  DOI：

  10.1021/jm00146a013

文献信息

• [EN] IMIDAZOLINE RECEPTOR TYPE 1 LIGANDS FOR USE AS THERAPEUTICS<br/>[FR] LIGANDS DU RÉCEPTEUR AUX IMIDAZOLINES DE TYPE 1 À UTILISER EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：RIDEOUT DARRYL

  公开号：WO2016105448A1

  公开（公告）日：2016-06-30

  This disclosure provides compounds and compositions for use as analgesics and for the treatment of various conditions, such as pain, headaches, allodynia, and fibromyalgia. The disclosure also provides compounds that are ligands, and in some embodiments, modulators (e.g., agonists), for the imidazoline receptor type 1.

  本公开提供了作为止痛剂和用于治疗各种病症的化合物和组合物，如疼痛、头痛、触痛和纤维肌痛。本公开还提供了作为嘌呤受体1的配体的化合物，有些实施例中还提供了对其的调节剂（例如，激动剂）。
• a2-Adrenoceptor Ligands
  申请人：Rozas Hernando Maria Isabel

  公开号：US20100160332A1

  公开（公告）日：2010-06-24

  The adrenergic receptors or adrenoceptors are a family of G-protein coupled receptors split into α and β subclasses. The adrenoceptors have important roles in regulating a myriad of physiological conditions and their malfunction has been implicated in the pathophysiology of a number of diseases. Disclosed herein are a series of novel compounds which are ligands of the alpha2-adrenoceptor (α 2 -ARs) subclass of adrenergic receptors. The invention also provides for pharmaceutical compositions comprising the novel compounds. The compounds are suitable for use in the manufacture of medicaments for the treatment of α 2 -ARs associated disorders, such as depression and schizophrenia.

  肾上腺素受体或肾上腺素受体是一类G蛋白偶联受体家族，分为α和β亚类。肾上腺素受体在调节多种生理条件中起着重要作用，其功能异常已被认为与多种疾病的病理生理有关。本文披露了一系列新颖化合物，这些化合物是肾上腺素受体中α2-肾上腺素受体（α2-ARs）亚类的配体。本发明还提供了包含这些新颖化合物的药物组合物。这些化合物适用于制造用于治疗与α2-肾上腺素受体相关疾病的药物，如抑郁症和精神分裂症。
• [EN] COMPOUNDS FOR USE AS PAIN THERAPEUTICS<br/>[FR] COMPOSÉS DESTINÉS À ÊTRE UTILISÉS EN TANT QU'AGENTS THÉRAPEUTIQUES CONTRE LA DOULEUR
  申请人：LEDERMAN SETH

  公开号：WO2016105449A1

  公开（公告）日：2016-06-30

  This disclosure provides compounds and compositions for use as analgesics and for the treatment of one or more conditions selected from: pain; psychic pain; psychological pain; psychiatric pain; depression; allodynia; fibromyalgia; fibromyalgia-ness; central sensitization; centralization; regional pain syndrome; temporomandibular joint syndrome (TMJ); lower back pain; interstitial cystitis; Gulf War syndrome; visceral pain; phantom limb painj.kidney stones; gout; neuropathic pain; post-herpetic neuralgia; diabetic neuropathy; sickle cell pain; priapism; nociceptive pain; post-operative pain; orthopedic injury pain; bunionectomy; dental extraction; pain after severed spinal cord injury; osteoarthritis; rheumatoid arthritis; Lyme disease; Parkinson's disease; opioid-induced constipation; an opioid withdrawal symptom; pain associated with post-traumatic stress disorder (PTSD); and combinations of any of the foregoing conditions. This disclosure also provides compounds that are ligands, and in some embodiments, modulators (e.g., agonists), for the imidazoline receptor type 1.

  本公开提供了用作镇痛剂和用于治疗以下一种或多种疾病的化合物和组合物：疼痛；心理疼痛；心理疼痛；精神疼痛；抑郁症；痛觉过敏；纤维肌痛；纤维肌痛症；中枢敏感化；中枢化；区域性疼痛综合征；颞下颌关节综合征（TMJ）；腰部疼痛；间质性膀胱炎；海湾战争综合征；内脏疼痛；幻肢疼痛；肾结石；痛风；神经性疼痛；带状疱疹后神经痛；糖尿病性神经病；镰状细胞疼痛；阴茎长时间勃起症；伤害性疼痛；术后疼痛；骨科损伤疼痛；拇外翻术；牙科拔牙；断裂脊髓损伤后疼痛；骨关节炎；类风湿关节炎；莱姆病；帕金森病；阿片类药物引起的便秘；阿片类药物戒断症状；与创伤后应激障碍（PTSD）相关的疼痛；以及上述任何疾病的组合。本公开还提供了作为咪唑啉受体类型1的配体的化合物，有些实施例中是调节剂（例如，激动剂）。
• GUANIDINE BASED COMPOUNDS
  申请人：Rozas Hernando Maria Isabel

  公开号：US20100331384A1

  公开（公告）日：2010-12-30

  The adrenergic receptors or adrenoceptors are a family of G-protein coupled receptors split into α and β subclasses. The adrenoceptors have important roles in regulating a myriad of physiological conditions and their malfunction has been implicated in the pathophysiology of a number of diseases. Disclosed herein are a series of novel guanidine and 2-aminoimidazoline compounds which are ligands of the alpha2-adrenoceptor (α2-ARs) subclass of adrenergic receptors. The invention also provides for pharmaceutical compositions comprising the novel compounds. The compounds are suitable for use in the manufacture of medicaments for the treatment of α2-ARs associated disorders, such as depression, schizophrenia, glaucoma and analgesia.

  肾上腺素受体或肾上腺素受体是一类G蛋白偶联受体家族，分为α和β亚类。肾上腺素受体在调节多种生理条件中起着重要作用，其功能失调已被认为与多种疾病的病理生理有关。本文披露了一系列新型胍啶和2-氨基咪唑啉化合物，它们是肾上腺素受体的α2-亚型（α2-ARs）亚类的配体。该发明还提供了包含这些新型化合物的药物组合物。这些化合物适用于制造用于治疗与α2-ARs相关疾病的药物，如抑郁症、精神分裂症、青光眼和镇痛的药物。
• COMPOSITIONS OF (-)-E-10-OH-NT AND METHODS FOR THEIR SYNTHESIS AND USE
  申请人：LE BOURDONNEC Bertrand

  公开号：US20080275131A1

  公开（公告）日：2008-11-06

  This present disclosure provides compositions comprising E-10-OH-NT metabolites of AT and NT, methods for their synthesis and methods for their use.

  本公开提供了包含AT和NT的E-10-OH-NT代谢物的组合物，以及它们的合成方法和使用方法。